Skip to main content

Advertisement

Table 2 Change in PANSS and CGAS from baseline to 6-month end point a

From: An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

  PBO/RIS RIS/RIS Direct-enroll All subjects
PANSS (n = 46) (n = 289) (n = 50) (N = 385)
Total     
Baseline, mean (SD) 84.7 (16.8) 72.1 (19.4) 83.9 (13.5) 75.1 (19.2)
Change, mean (SD) ‐25.7 (18.2) ‐10.5 (17.7) ‐19.9 (16.2) ‐13.6 (18.4)
p value <-0.001 <-0.001 <-0.001 <-0.001
Positive symptoms     
Baseline, mean (SD) 23.6 (6.0) 19.1 (5.7) 23.1 (4.7) 20.1 (5.9)
Change, mean (SD) -8.7 (6.5) -3.2 (5.4) -6.2 (5.2) -4.2 (5.8)
p value <-0.001 <-0.001 <-0.001 <-0.001
Negative symptoms     
Baseline, mean (SD) 21.5 (5.4) 19.0 (6.5) 21.2 (4.4) 19.6 (6.2)
Change, mean (SD) -5.7 (5.4) -2.9 (5.6) -4.6 (4.1) -3.4 (5.5)
p value <-0.001 <-0.001 <-0.001 <-0.001
Anxiety/depression     
Baseline, mean (SD) 9.7 (3.3) 8.4 (3.1) 10.1 (3.0) 8.8 (3.2)
Change, mean (SD) -3.3 (3.2) -1.2 (3.5) -2.3 (3.1) -1.6 (3.5)
p value < -0.001 < -0.001 < -0.001 < -0.001
Disorganized thoughts     
Baseline, mean (SD) 19.4 (4.3) 17.3 (5.7) 19.8 (4.1) 17.9 (5.4)
Change, mean (SD) -5.0 (4.1) -2.4 (4.3) -4.5 (4.3) -3.0 (4.4)
p value <-0.001 <-0.001 <-0.001 <-0.001
Uncontrolled hostility/excitement     
Baseline, mean (SD) 10.5 (3.6) 8.4 (3.3) 9.6 (3.1) 8.8 (3.4)
Change, mean (SD) -3.1 (4.0) -1.0 (3.5) -2.3 (3.2) -1.4 (3.6)
p value <0.001 <0.001 <0.001 <0.001
CGAS (n = 45) (n = 174) (n = 41) (n = 260)
Baseline, mean (SD) 51.8 (16.7) 55.9 (15.5) 51.1 (15.4) 54.4 (15.8)
Change, mean (SD) 16.3 (13.7) 7.5 (14.3) 14.4 (12.2) 10.1 (14.3)
p value <-0.001 <-0.001 <-0.001 <-0.001
  1. CGAS, Children’s Global Assessment Scale; PANSS, positive and negative syndrome score; PBO, placebo; RIS, risperidone; SD, standard deviation.
  2. aIntent-to-treat population, last observation carried forward.
  3. Note: p values are from a within-group test of change from baseline, based on two-sided paired t test.